Management of the Axilla in Early-Stage Breast Cancer: Ontario Health (Cancer Care Ontario) and ASCO Guideline.
Muriel BrackstoneFulvia G BaldassarreFrancisco E PereraTulin D CilMariana Chavez Mac GregorIan S DayesJay EngelJanet K HortonTari A KingAnat KorneckiRalph GeorgeSandip K SenGuptaPatricia A SpearsAndrea F EisenPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021)
Recommendations are issued for each of the objectives of this guideline: (1) To determine which patients with early-stage breast cancer require axillary staging, (2) to determine whether any further axillary treatment is indicated for women with early-stage breast cancer who did not receive NAC and are sentinel lymph node-negative at diagnosis, (3) to determine which axillary strategy is indicated for women with early-stage breast cancer who did not receive NAC and are pathologically sentinel lymph node-positive at diagnosis (after a clinically node-negative presentation), (4) to determine what axillary treatment is indicated and what the best timing of axillary treatment for women with early-stage breast cancer is when NAC is used, and (5) to determine which are the best methods for identifying sentinel nodes.Additional information is available at www.asco.org/breast-cancer-guidelines.